Teachers Retirement System of The State of Kentucky Has $11.03 Million Stock Position in Boston Scientific Corporation $BSX

Key Points

• Teachers Retirement System of Kentucky cut its stake in Boston Scientific by 32.5% in Q4 and now holds 115,669 shares valued at approximately $11.03 million.
• CEO Michael F. Mahoney sold 160,901 shares on Feb. 2 for about $15.04 million, trimming his position by 10.23% (company insiders now own ~0.34% of BSX).
• Boston Scientific reported Q1 revenue up ~11.6% to $5.2 billion and EPS of $0.80 (beat), but management trimmed 2026 guidance and several analysts cut targets, fueling recent share weakness and mixed ratings.

Teachers Retirement System of The State of Kentucky lowered its stake in shares of Boston Scientific Corporation (NYSE:BSX - Free Report) by 32.5% during the fourth quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The fund owned 115,669 shares of the medical equipment provider's stock after selling 55,779 shares during the quarter. Teachers Retirement System of The State of Kentucky's holdings in Boston Scientific were worth $11,029,000 as of its most recent SEC filing.

Several other hedge funds and other institutional investors have also recently added to or reduced their stakes in BSX. FWL Investment Management LLC acquired a new position in shares of Boston Scientific during the second quarter worth approximately $26,000. Murphy & Mullick Capital Management Corp grew its stake in shares of Boston Scientific by 200.0% during the third quarter. Murphy & Mullick Capital Management Corp now owns 255 shares of the medical equipment provider's stock valued at $25,000 after purchasing an additional 170 shares during the last quarter. Financial Consulate Inc. acquired a new stake in shares of Boston Scientific in the third quarter valued at approximately $25,000. United Community Bank raised its position in Boston Scientific by 115.7% in the 3rd quarter. United Community Bank now owns 274 shares of the medical equipment provider's stock worth $27,000 after purchasing an additional 147 shares during the last quarter. Finally, Colonial Trust Co SC raised its position in Boston Scientific by 502.2% in the 3rd quarter. Colonial Trust Co SC now owns 277 shares of the medical equipment provider's stock worth $27,000 after purchasing an additional 231 shares during the last quarter. Institutional investors and hedge funds own 89.07% of the company's stock.

Insider Transactions at Boston Scientific

In other news, CEO Michael F. Mahoney sold 160,901 shares of the business's stock in a transaction dated Monday, February 2nd. The stock was sold at an average price of $93.49, for a total transaction of $15,042,634.49. Following the completion of the transaction, the chief executive officer directly owned 1,411,735 shares in the company, valued at approximately $131,983,105.15. The trade was a 10.23% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Company insiders own 0.34% of the company's stock.

Boston Scientific Stock Performance

Shares of Boston Scientific stock opened at $62.01 on Monday. The firm has a fifty day moving average of $68.45 and a two-hundred day moving average of $85.63. The company has a debt-to-equity ratio of 0.46, a quick ratio of 1.08 and a current ratio of 1.62. The stock has a market capitalization of $92.16 billion, a price-to-earnings ratio of 25.95, a PEG ratio of 1.10 and a beta of 0.78. Boston Scientific Corporation has a 52 week low of $59.38 and a 52 week high of $109.50.

Boston Scientific (NYSE:BSX - Get Free Report) last posted its quarterly earnings results on Wednesday, April 22nd. The medical equipment provider reported $0.80 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.79 by $0.01. Boston Scientific had a return on equity of 19.68% and a net margin of 17.29%.The business had revenue of $5.20 billion for the quarter, compared to analyst estimates of $5.19 billion. During the same period last year, the company earned $0.75 EPS. The firm's revenue was up 11.6% on a year-over-year basis. Boston Scientific has set its Q2 2026 guidance at 0.820-0.840 EPS and its FY 2026 guidance at 3.340-3.410 EPS. As a group, equities research analysts predict that Boston Scientific Corporation will post 3.37 EPS for the current year.

Analyst Ratings Changes

A number of research analysts have commented on the company. Jefferies Financial Group decreased their price objective on Boston Scientific from $110.00 to $100.00 and set a "buy" rating on the stock in a research report on Wednesday, April 22nd. UBS Group dropped their target price on Boston Scientific from $120.00 to $105.00 and set a "buy" rating for the company in a research report on Tuesday, March 17th. Sanford C. Bernstein reiterated an "outperform" rating and issued a $112.00 price target on shares of Boston Scientific in a report on Friday, February 6th. Morgan Stanley lowered their price objective on Boston Scientific from $130.00 to $118.00 and set an "overweight" rating for the company in a research report on Thursday, February 5th. Finally, Wall Street Zen cut Boston Scientific from a "buy" rating to a "hold" rating in a report on Saturday, March 28th. One investment analyst has rated the stock with a Strong Buy rating, twenty-two have given a Buy rating and two have given a Hold rating to the stock. According to data from MarketBeat.com, the stock presently has an average rating of "Moderate Buy" and an average target price of $93.91.

Trending Headlines about Boston Scientific

Here are the key news stories impacting Boston Scientific this week:

• Positive Sentiment: Q1 results beat consensus — revenue grew ~11.6% and EPS topped estimates, showing underlying demand and execution that underpinned an initial share pop after the report. Boston Scientific Corporation NYSE: BSX Q1 2026 Earnings Call Transcript
• Positive Sentiment: Unusual call-option activity — heavy call buying was reported around the earnings period, indicating some traders are positioning for a rebound or event-driven upside. Traders Purchase High Volume of Boston Scientific Call Options NYSE: BSX
• Neutral Sentiment: Analyst views are mixed and the investment story is being reset — several coverage teams trimmed fair-value estimates and split between seeing a buy opportunity versus emphasizing execution risk. This creates divergence in short‑to‑medium term expectations. How The Investment Story Is Resetting For Boston Scientific (BSX) After Recent Analyst Shifts
• Negative Sentiment: Company trimmed 2026 profit and revenue outlook — management lowered full‑year guidance (Q2 trough flagged), which directly reduced near‑term earnings visibility and is the primary driver of the pullback. Boston Scientific cuts 2026 profit forecast, trims revenue growth view
• Negative Sentiment: Analysts slashed price targets after Q1/guidance — multiple firms trimmed targets (Truist, Baird, Needham, others), which amplifies selling pressure and reduces near‑term analyst support. Boston Scientific Analysts Slash Their Forecasts After Q1 Earnings
• Negative Sentiment: Multiple securities‑class action notices and law‑firm solicitations — several firms are soliciting lead‑plaintiff candidates tied to a July 2025–Feb 2026 class period, increasing legal risk and potential headline volatility. Boston Scientific Corporation (BSX) Shareholders Who Lost Money Have Opportunity to Lead Securities Fraud Lawsuit
• Negative Sentiment: Downgrades and new 52‑week low headlines — coverage noting downgrades and a 52‑week low contributes to technical selling and stops being hit. Boston Scientific NYSE: BSX Hits New 52-Week Low After Analyst Downgrade

About Boston Scientific

Boston Scientific Corporation NYSE: BSX is a global medical device company that develops, manufactures and markets a broad portfolio of products used in less-invasive medical procedures. Founded in 1979 by John Abele and Peter Nicholas, the company is headquartered in Marlborough, Massachusetts, and focuses on technologies that enable physicians to treat a wide range of cardiovascular, digestive, urologic, pulmonary and chronic pain conditions without open surgery.

Boston Scientific's activities span product development, clinical research, regulatory affairs and commercial sales.

Want to see what other hedge funds are holding BSX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Boston Scientific Corporation (NYSE:BSX - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.